Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...

The stock's rise snapped a five-day losing streak.

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim Cramer’s radar recently. On Monday’s episode of Mad Money, Jim Cramer ...